To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Incyte Corporation
Related studies linked through entity extraction aliases.
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
- Status
- TERMINATED
- Phase
- PHASE3
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
- Status
- TERMINATED
- Phase
- PHASE3
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
- Status
- COMPLETED
- Phase
- PHASE3
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- Status
- COMPLETED
- Phase
- PHASE2
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
- Status
- TERMINATED
- Phase
- PHASE2
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
- Status
- TERMINATED
- Phase
- PHASE2
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
- Status
- TERMINATED
- Phase
- PHASE3
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- Status
- RECRUITING
- Phase
- PHASE2
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
- Status
- COMPLETED
- Phase
- PHASE3